Navigation Links
Genprex Announces New Patent Issuance in Japan
Date:10/18/2011

AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation for lung cancer patients in the U.S.

"Japan represents an important clinical population," stated Chief Operating and Financial Officer Greg Heinlein. "We intend to include Japanese collaborators in our development and commercialization plans and have begun to establish key relations within the region, including appointments of leading oncology experts to our Medical and Scientific Advisory Board."

Genprex controls a portfolio of biomedical technologies including targeted molecular therapeutics for cancer and other diseases. The novel technologies, including those licensed exclusively from The University of Texas MD Anderson Cancer Center, are protected by 15 issued patents and 9 pending applications in major market areas. These broadly applicable technologies have been the subject of more than 20 peer-reviewed scientific publications in the fields of cancer, genomics and molecular biology.

About Oncoprex™Oncoprex is a nanomolecular therapy harnessing the TUSC2 tumor suppressor. TUSC2 defects are associated with most major cancers and >85% of lung cancers. Intravenous Oncoprex induces apoptosis or programmed cell death in cancer cells and controls cell signaling and inflammation to fight cancer along universal cancer pathways. In phase I clinical testing of Stage IV lung cancer patients, Oncoprex monotherapy was well tolerated and demonstrated clinically significant anti-cancer activity in primary lung tumors and metastatic tumors, including liver and pancreas. A phase II clinical trial evaluating Oncoprex in combination with Tarceva® (erlotinib) is planned for 2012. The trial will enroll lung cancer patients without the EGFR mutation and patients with EGFR mutations who have become unresponsive to erlotinib.

About GenprexGenprex, Inc. is a privately held, clinical-stage biopharmaceutical company developing nanomolecular therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. For more information about Genprex click here. Tarceva® is a registered trademark of the Roche Group, including Genentech and Chugai, and of Astellas Pharma.Contact:

Greg HeinleinPhone:

512-597-5900www.genprex.com
'/>"/>

SOURCE Genprex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development
2. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
3. Hologic Announces Jury Verdict in Patent Infringement Suit
4. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
5. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
6. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
7. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
8. Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition
9. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Express Scripts Announces Third Quarter 2011 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... LOS ANGELES , Feb. 10, 2016  Oxis ... blood cancer drug, OXS-1550, was described as a "clinical ... with the drug went into complete cancer remission. ... the University of Minnesota Masonic Cancer Center. ... the University of Minnesota Masonic Cancer Center. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... and OR AKIVA, Israel ... Regentis Biomaterials Ltd., a leader in the field ... D investment round on February 5, 2016. The $15 ... ("Haisco"), a leading Chinese pharmaceutical manufacturer, and was ... Vitalife Partners, Generali Financial Holdings and both the Technion ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... As part ... two webinars in February 2016. Each webinar features a dynamic expert and thoughtful ... benefit their athletes, patients and facilities. Both events are free to attend, but ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is ... leading bottled water brand owners that topped the list as a result of their ... conversion. The premier brand was Tibet 5100, a top notch water company that specializes ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
Breaking Medicine News(10 mins):